Market Overview:
The global Polycystic Ovary Syndrome (PCOS) Treatment Market is estimated to be valued at US$ 1,086.6 million in 2023 and is expected to exhibit a CAGR of 4.86% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women of reproductive age. Symptoms include irregular or no menstrual periods, excess androgen (male hormones) levels, difficulties getting pregnant, and small cysts in the ovaries. Oral contraceptives, insulin-sensitizing agents such as metformin, and Antiandrogens are commonly used treatments for managing PCOS symptoms and improving fertility. These medications help regulate the menstrual cycle and reduce male hormone levels.
Market key trends:
One of the key trends driving the PCOS treatment market growth is the steady rise in diagnosis rates worldwide. Factors such as the growing prevalence of obesity and insulin resistance, which are significant risk factors for PCOS, have contributed to this upward trend. Additionally, increased awareness about PCOS among women and physicians is leading to more diagnosis. Early identification and therapy can help manage symptoms and prevent long-term health issues. The market is also witnessing the entry of new drug formulations and combination therapies for improving treatment efficacy. For example, recent years have seen approval of newer drugs combining metformin with other agents like oral contraceptives. This promises enhanced outcomes for women suffering from PCOS.
Porter’s Analysis
Threat of new entrants: The presence of established players and requirement of high R&D investments act as a barrier for new entrants in the market.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative treatment options.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitute raw materials.
Threat of new substitutes: Threat of new substitutes is low as there are limited treatment alternatives available for PCOS currently.
Competitive rivalry: The market is highly competitive with major players competing in terms of product offerings and pricing.
Key Takeaways
The Global Polycystic Ovary Syndrome (PCOS) Treatment Market Demand is expected to witness high growth, exhibiting a CAGR of 4.86% over the forecast period, due to increasing prevalence of PCOS among women population and rising awareness.
North America is expected to dominate the global PCOS treatment market during the forecast period. This is attributed to the rising cases of PCOS, advanced healthcare facilities, and growing obese population in the region. Europe is also expected to register robust growth owing to increasing healthcare spending and government support for research activities in the region.
Key players operating in the PCOS treatment market include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., Evotec SE, McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG.
